<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The mechanism of action of calcium channel modulators, a class of drugs that includes 3 chemical groups--1,4-<z:chebi fb="0" ids="50075">dihydropyridines</z:chebi>, phenylalkylamines and <z:chebi fb="0" ids="48684">benzothiazepines</z:chebi>--has been extensively reviewed </plain></SENT>
<SENT sid="1" pm="."><plain>The best known representatives of these 3 groups are <z:chebi fb="1" ids="7565">nifedipine</z:chebi>, <z:chebi fb="1" ids="9948">verapamil</z:chebi> and diltiazem, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>These drugs bind reversibly, stereospecifically and with high affinity to both the membrane-bound and the purified receptor complex </plain></SENT>
<SENT sid="3" pm="."><plain>Non-<z:chebi fb="0" ids="50075">dihydropyridines</z:chebi> allosterically regulate <z:chebi fb="0" ids="50075">dihydropyridine</z:chebi> binding </plain></SENT>
<SENT sid="4" pm="."><plain>This has been shown by using (-) [3H]202-791 and (+) [3H]PN200-110 as labeled ligands </plain></SENT>
<SENT sid="5" pm="."><plain>The purified receptor complex that possesses binding sites for <z:hpo ids='HP_0000001'>all</z:hpo> 3 chemical groups is likely to be related to the voltage-dependent calcium channel </plain></SENT>
<SENT sid="6" pm="."><plain>As the result of a drug-receptor interaction, voltage-dependent calcium channels are either activated or inactivated </plain></SENT>
<SENT sid="7" pm="."><plain>The drugs that activate channels act by promoting long-lasting channel openings </plain></SENT>
<SENT sid="8" pm="."><plain>The drugs that inhibit calcium channels, the calcium entry-blocking agents, act by preventing channel openings upon membrane depolarization </plain></SENT>
<SENT sid="9" pm="."><plain>A complex pharmacologic, electrophysiologic, biochemical, immunologic and molecular genetic approach is required to determine the molecular mechanism of action of calcium channel modulators </plain></SENT>
<SENT sid="10" pm="."><plain>Clinically, calcium entry-blocking agents are recommended for the treatment of <z:hpo ids='HP_0001681'>angina pectoris</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, posthemorrhagic <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e>, <z:hpo ids='HP_0004755'>supraventricular tachycardia</z:hpo>, <z:hpo ids='HP_0002076'>migraine</z:hpo> and <z:hpo ids='HP_0002099'>asthma</z:hpo> and the protection of the ischemic myocardium </plain></SENT>
</text></document>